FY2025 EPS Estimates for JSPR Raised by Cantor Fitzgerald

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Equities research analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Jasper Therapeutics in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($4.17) for the year, up from their previous forecast of ($4.24). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

A number of other research firms have also recently commented on JSPR. JMP Securities reissued a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research note on Monday, January 6th. HC Wainwright dropped their price objective on Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a report on Friday, January 10th. Royal Bank of Canada reduced their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research report on Thursday, January 9th. UBS Group began coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $38.00 target price on the stock. Finally, BMO Capital Markets started coverage on Jasper Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. Eleven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $64.44.

Jasper Therapeutics Stock Performance

Shares of NASDAQ JSPR opened at $5.68 on Thursday. The stock has a market cap of $85.21 million, a PE ratio of -1.20 and a beta of 2.11. Jasper Therapeutics has a fifty-two week low of $4.55 and a fifty-two week high of $31.01. The stock has a fifty day moving average of $8.99 and a 200-day moving average of $16.56.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Braidwell LP acquired a new stake in Jasper Therapeutics during the 3rd quarter worth $9,091,000. Boxer Capital Management LLC purchased a new position in Jasper Therapeutics in the fourth quarter valued at about $7,483,000. Integral Health Asset Management LLC boosted its position in Jasper Therapeutics by 85.7% during the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $13,897,000 after purchasing an additional 300,000 shares in the last quarter. Ally Bridge Group NY LLC increased its stake in shares of Jasper Therapeutics by 82.7% during the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after purchasing an additional 180,852 shares in the last quarter. Finally, Soleus Capital Management L.P. raised its stake in Jasper Therapeutics by 11.2% in the 4th quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company’s stock valued at $31,951,000 after purchasing an additional 150,755 shares during the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.